The key role played by fucose in glycoprotein and cellular function has prompted significant research toward identifying recombinant and biochemical strategies for blocking its incorporation into proteins and membrane structures. Technologies surrounding engineered cell lines have evolved for the inhibition of in vitro fucosylation, but they are not applicable for in vivo use and drug development. To address this, we screened a panel of fucose analogues and identified 2-fluorofucose and 5-alkynylfucose derivatives that depleted cells of GDPfucose, the substrate used by fucosyltransferases to incorporate fucose into protein and cellular glycans. The inhibitors were used in vitro to generate fucose-deficient antibodies with enhanced antibody-dependent cellular cytotoxicity activities. When given orally to mice, 2-fluorofucose inhibited fucosylation of endogenously produced antibodies, tumor xenograft membranes, and neutrophil adhesion glycans. We show that oral 2-fluorofucose treatment afforded complete protection from tumor engraftment in a syngeneic tumor vaccine model, inhibited neutrophil extravasation, and delayed the outgrowth of tumor xenografts in immune-deficient mice. The results point to several potential therapeutic applications for molecules that selectively block the endogenous generation of fucosylated glycan structures.
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glycosylation | carbohydrate | metabolism | selectin M ore than 50% of eukaryotic proteins are posttranslationally modified with glycan structures that impact protein folding, stability, trafficking, subcellular localization, secretion, and biological activities (1) (2) (3) . On the cell surface, carbohydrates are involved in cell-cell recognition, and altered carbohydrate structures are often associated with cellular clearance, inflammation, autoimmunity and cancer (1) (2) (3) (4) (5) (6) . To gain insight into the roles that protein carbohydrates play in protein activity and biology, considerable research has been directed toward perturbing their structures and assessing changes in protein function (7) (8) (9) (10) (11) (12) . A common approach has been through the utilization of novel monosaccharides that become incorporated or alter protein glycan structures. These include such molecules as 5-alkynylfucose (10, 12) , 5-thio-N-acetylglucosamine (13), 5-or 6-fluoro-galactofuranose (7), 3-fluoro-N-acetyl-neuraminic acid (11) , azidosugars such as N-azidoacetylgalactosamine or N-azidoacetylglucosamine (1, 14) , 4-fluoro-glucosamine (15), 5-thiofucose (16) , and 2-fluorofucose peracetate (11, 17) . Another method to modify protein glycans involves inhibition of enzymes that mediate glycosylation or glycan maturation with agents such as castanospermine (18) , swainsonine (19) , and the anti-type 1 Gaucher disease drug, N-butyldeoxynojirimycin (20) . However, these latter inhibitors can generate sweeping changes in glycan structure, and typically do not provide detailed information concerning particular interactions between glycoproteins and their receptors. To analyze glycan functions involved in pathogenesis, there is a need for more selective glycosylation inhibitors that induce highly specific and well-defined structural alterations.
Many protein carbohydrates, such as those shown in Fig. 1 , contain L-fucose (21) , a sugar that is distinguished from other mammalian sugars as a result of its L-configuration and the lack of a hydroxyl group at the 6-position (Fig. 2A) . These fucose containing carbohydrates can be biologically significant. For example, mAbs devoid of fucose (G0; Fig. 1 ) bind to Fcγ receptor IIIA (FcγRIIIA; CD16) more strongly and have significantly higher antibody-dependent cellular cytotoxicity (ADCC) than corresponding fucosylated mAbs (G0F) in vitro and in vivo. Several clinical trials of fucose-deficient mAbs are under way (22) (23) (24) (25) (26) (27) , and mogamulizumab, an anti-CC chemokine receptor 4 mAb lacking core fucosylation has received marketing approval in Japan for the treatment of relapsed or refractory adult T-cell leukemia/ lymphoma (28) . Other fucosylated glycans of interest include sialyl Lewis X (sLeX), sialyl Lewis A, and Lewis Y (LeY), which are on cell surfaces and have been associated with malignancy, tumor progression, and inflammation (6, 21, 29, 30) .
Because of the important role that fucose plays in protein and cellular functions, specific inhibitors of its incorporation could have significant applications in basic research and therapy. One such inhibitor, 2-fluorofucose peracetate (2) was recently reported to block fucosylation of a cancer cell line in vitro, altering its ability to bind E-selectin (11) . We wished to more globally explore the impact that fucose plays at protein, cellular, and biological levels by identifying specific biochemical inhibitors that could be applied in vitro and in vivo. Here, we describe several molecules that are capable of blocking protein fucosylation and show that 2-fluorofucose (1), 5-alkynylfucose (4), and their corresponding peracetylated derivatives (2 and 5) can be used for the in vitro generation of fucose-deficient mAbs with high effector function activities. We provide an overview of the mechanism of activity, and show that 1 is orally bioavailable and exhibits significant in vivo activities in models of cancer, cancer vaccines, and modulation of leukocyte trafficking.
Results

Identification and Mechanism of Activity of Protein Fucosylation
Inhibitors. A synthetically derived library of ∼200 fucose-related molecules was generated in which the hydroxyl groups were replaced with heteroatom substituents or esterified for cellular penetration, alkyl groups were used to replace the 5-methyl group, and stereochemical configurations about the ring system were altered (17) . The ability of these molecules to inhibit protein fucosylation was determined by exposing CHO cells that express humanized 1F6 (h1F6), an IgG 1 mAb directed against the CD70 antigen (31) to 50 to 1,000 μM of each test article, isolating the mAb from culture supernatants, and analyzing changes in the molecular weight of carbohydrate structures by liquid chromatography-mass spectrometry (LC-MS) of the intact heavy chains. The most active molecules from the screen were 2 and 5 ( Fig. 2A) , which gave 98% and 95% inhibition of mAb fucosylation, respectively ( Fig. 2 B and  C) , as determined by LC-MS of glycopeptides derived from mAb trypsin digests, compared with 3% nonfucosylated mAb in native h1F6. Minor amounts (≤2%) of fucosylated glycopeptides were obtained, together with glycopeptides that incorporated 1 (0.2%) and 4 (3%) in place of fucose. There was no measureable impact on mAb production or cell viability (Fig. S1 ). Similar results were obtained in CHO cells treated with compounds 1 and 4, which fully inhibited the fucosylation of the h1F6 mAb at the lowest screening concentration tested (50 μM; Fig. S2 ). The results suggest that deacetylation occurs readily within CHO cells, leading to the generation of 1 and 4 from 2 and 5, respectively, which can then lead to the inhibition of fucosylation.
Fucose is incorporated into glycoprotein oligosaccharides via a fucosyl transfer reaction using GDP-fucose as donor, which is generated from the free sugar or through the de novo pathway starting from GDP-mannose (21) (Fig. 3A) . The media used to grow mAb producing CHO cells in vitro is fucose-deficient, requiring nearly sole dependence on the de novo pathway, of which one of the central enzymes involved is GDP-mannose 4,6-dehydratase (GMD). To determine if the fucose analogues 2 and 5 led to GMD inhibition, the GDP derivatives 3 and 6 ( Fig. 2A) were prepared and tested in vitro on recombinant human GMD, which is susceptible to feedback inhibition by GDP-fucose (21) . The GDP derivatives 3 and 6 inhibited GMD activity, albeit with lower potency compared with GDP-fucose (Fig. 3B) . Importantly, CHO cells treated with 2 and 5 had greatly reduced levels of GDP-fucose (Fig. 3C) , suggesting that inhibitory concentrations of 3 and 6 were formed inside cells, likely by the same fucose-modifying enzymes that generate GDP-fucose through the salvage pathway. We confirmed their presence at relevant inhibitory concentrations by reversed-phase HPLC analysis under conditions where depletion of GDP-fucose is observed (Fig. S3) . Therefore, depletion of intracellular GDP-fucose pools with resulting blockade of the de novo pathway is the most likely mechanism for the activity of the lead fucosylation inhibitors in CHO cells. An additional mode of activity may involve inhibition of fucosyltransferase (Fut) enzymes. For antibody fucosylation, this involves Fut VIII (Fut8), which catalyzes the formation of the α(1, 6)Fuc bond. Compound 3 has been previously shown to inhibit human Futs in vitro (11, 17) . We demonstrated that hamster Fut8 was inhibited by 3 and 6, with 6 showing even more pronounced inhibitory activity than the known (32) inhibitor GDP (Fig. 3D ).
In Vitro Activities of Fucose-Deficient Proteins. ADCC is mediated by interactions between the Fc regions of target cell bound antibodies with FcγRIIIA receptors on effector cell surface membranes. When it has been engaged, the activated effector cell induces specific lysis of the target cell through the release of cytotoxic enzymes and pore-forming agents. The vast majority of antibodies found in nature are fucosylated and bind to FcγRIIIA with lower affinities compared with the less abundant forms that lack fucose (25, 26) . The binding data for purified anti-CD30 cAC10 mAb (IgG 1 ) to human FcγRIIIA was consistent with this, in that fucose-deficient versions of cAC10 made in CHO cells treated with 2 or 5 showed increased binding compared with the parental fucosylated mAb (Fig. 4A) . Inhibition of fucosylation provided enhanced ADCC activity, as evidenced by increased lysis of tumor cells mediated by FcγRIIIA-positive natural killer cells in the presence of fucose-deficient cAC10, h1F6, or hS2C6 (anti-CD40; IgG 1 ; Fig. 4B ). It is therefore possible to derive higher ADCCmediating mAbs in vitro by using molecules that block the biochemical incorporation of fucose into the carbohydrate structure.
As all Futs use GDP-fucose as a substrate, it was anticipated that fucose-containing structures other than the α(1, 6)fucosyl linkage on IgGs would also be inhibited by 2 and 5 through inhibition of GMD and subsequent depletion of cellular GDP-fucose pools. To investigate this, we cultured human LS174T colorectal cells in the presence of noncytotoxic concentrations of 2 or 5, and assessed the impact on membrane-bound fucosylated epitopes, such as the blood group antigens LeX and LeY ( Fig. 1) , by using the fucose lectin Lens culinaris agglutinin-A (LCA) (33) and the mAbs cBR96 (anti-LeY) (34) and SSEAI (anti-LeX) (35) . FACS analysis (Fig. 4C ) showed that treatment with 2 and 5 led to diminished binding, demonstrating that these molecules are capable of blocking the general incorporation of fucose into oligosaccharides on cancer cells, results that are in agreement with previously reported MS data collected with 2-treated HL-60 cells (11) . The deacetylated parent molecule 1 also inhibited LeX and LeY expression, whereas 4 had lower activity ( Fig. 4D ), possibly because of reduced cellular uptake. The functional effect of inhibiting fucosylation of LS174T cells with 1 is apparent from its diminished adherence to E-selectin-coated plates (Fig. 4E) .
In Vivo Applications. Preliminary tolerability data in mice were obtained before exploring biological applications for the fucosylation inhibitors. Compounds 1, 2, 4, and 5 were injected i.p. at 150 mg/kg daily for 1 wk, with no outward signs of toxicity. In addition, mice were provided with as much as 100 mM 1 continuously in their drinking water for 21 d. In both these experiments, there were no clinically significant observations with regard to health, and no impact on water consumption or weight gain.
The oral bioavailability of these compounds was determined by comparing serum concentrations from oral gavage vs. i.v. administration. The bioavailability of 1 (60-80%) proved to be twoto threefold higher than that of 4, and was in the range of values reported for simple monosaccharides (Fig. S4) (36) . Because of this, the low levels of incorporation within mAbs, and the effective blockade of fucosylated epitopes on cancer cell membranes, we focused further attention on the in vivo properties of 1.
To demonstrate a pharmacodynamic effect, we examined the fucosylation state of antibodies in circulation of mice that received 1 in their drinking water for 21 d at the concentrations shown in Fig. 5A . The fucose content of the serum IgG purified by Protein A was assessed via a dot-blot assay with Aspergillus oryzae l-fucosespecific lectin (AOL) (33) that binds to fucosylated glycoproteins. The AOL-binding signal of circulating IgGs from mice that received 10 mM or 100 mM oral 1 were greatly decreased compared with normal IgG. At 100 mM, the signal was below the detection limit of the assay, suggesting that the IgGs may have been completely devoid of fucose (Fig. 5A ). Improved effector function activity was anticipated based on the finding that fucose-deficient murine mAbs bound more strongly than their fucosylated counterparts to mouse Fcγ receptor IV (Fig. S5) , the corresponding receptor to human FcγRIIIA.
These results prompted us to investigate the use of 1 in a tumor vaccine model whereby an enhanced humoral immune response could be elicited by the generation of endogenous antitumor antibodies lacking fucose. For this, we turned to the well-established A20 lymphoma idiotype vaccine model, in which immunized mice have been shown to generate anti-idiotypic antibodies (37) (38) (39) . Idiotype vaccines exploit the finding that B-cell lymphomas express unique cell-surface Ig idiotypes, which can be used in the form of keyhole limpet hemocyanin (KLH) conjugates for active immunotherapy. Humoral and T-cell responses can contribute to tumor protection in the A20 (37-39) and other syngeneic tumor vaccine models (40) (41) (42) .
In the tumor vaccine experiment, immunocompetent BALB/c mice were immunized with the recombinant idiotype Fab that was chemically conjugated to KLH. Mice were then divided into groups that received 20 mM 1 in water or water alone as a control. Implantation of high tumor burdens (2.5 × 10 6 cells per mouse) of live A20 lymphoma cells in previously untreated mice led to rapid, synchronous lethality by day 24 (Fig. 5B) . The fucosylation inhibitor 1 provided greater than 1 wk survival benefit compared with the untreated control group, but all the animals eventually died of disease. As expected, immunization with the idiotype was also protective, but 80% of the animals receiving normal drinking water died by day 60. In contrast, complete protection from tumor outgrowth to day 90 was observed in immunized animals that received the fucosylation inhibitor 1 given in the period between the first boost through 21 d after tumor implantation. Circulating antibodies isolated from the mice treated with 1 at day 14 were devoid of fucose (Fig. S6) . Anti-idiotypic antibodies in the vaccinated group receiving oral 1 were likely minimally fucosylated, reflecting the composition in the endogenous pool. The results demonstrate that inhibition of fucosylation in vivo can lead to pronounced antitumor activities when combined with a tumor vaccine. Although a cellular immune response may play some role in this activity, an additional likely mechanism is through the formation of fucose-deficient anti-idiotype antibodies that have higher-affinity binding to mouse Fcγ receptor IV.
Having shown that the fucosylation inhibitor 1 provides some degree of antitumor activity in the unvaccinated arm of the disseminated A20 experimental metastasis model, we explored its activity as a chemotherapeutic agent. These studies were further prompted by reports that fucosylation is involved in tumor cell growth and adhesion, and cell-cell interactions in general (6, 21) . For these studies, we focused on human LS174T colorectal carcinoma tumors (LeX-and LeY-positive) grown in immunecompromised nude mice. Oral treatment of tumor-bearing mice with 1 (50 mM) for 1 wk before and 3 wk after LS174T tumor implantation resulted in inhibition of tumor outgrowth (Fig. 5C ). Similar results have been obtained in an array of tumor models, including the A20 model described earlier and the A20 model with treatment commencing 5 d after tumor implantation (Fig.  S7A) , and in Caki-1 renal cell cancer tumors in which reinitiation of fucose treatment 28 d after tumor implantation completely inhibited further tumor outgrowth (Fig. S7B) .
Inhibition of xenograft tumor cell surface fucosylation was observed by disaggregating the LS174T tumors from treated and untreated mice and staining them with known molecules that bind fucosylated glycoproteins of varying structures. Pronounced decreases in fucosylated LeX and LeY structures were measured with mAbs against these ligands as well as with fucose-binding lectins LCA, Aleuria aurantia lectin (43) , and AOL (Fig. 5D ), similar to that observed in the in vitro setting (Fig. 4D) . These results provide insight into a potential underlying mechanism for antitumor activity, as the fucosylated glycans LeX and LeY have been implicated in tumor progression (6, 21, 29) .
We also investigated the effects that inhibition of cellular fucosylation would have on neutrophil extravasation, as sLeX on circulating neutrophils mediates binding to E-selectin (CD62) and P-selectin (CD62P) on endothelial cell membranes, one of the first events leading to neutrophil extravasation from the bloodstream into the extravascular space (44) . The interaction is dependent on the presence of fucose in the sLeX structure (45) . We treated mice with 1 for 21 d and measured circulating neutrophil counts, together with their ability to bind to a recombinant mouse E-selectinFc fusion protein. At doses of 10 or 100 mM 1, blood neutrophil counts were considerably increased (Fig. 5E) , with concomitant loss in E-selectin binding (Fig. 5F ). P-selectin binding was reduced in a similar manner (Fig. S8) . The general inability of fucose-binding reagents to bind to cells treated with 1 suggests that there is a loss of functionality associated with their fucose epitopes, especially in the case of selectin reagents, which are natural receptors for fucosecontaining ligands.
The timing of the loss of antibody fucosylation and effects on Eselectin/neutrophil binding were determined, and it was found that maximal activities (at 2 and 14 d, respectively) corresponded to how rapidly these targets are turned over in vivo (46, 47) . The effects on neutrophils and antibody fucosylation were transient, in that circulating neutrophil and antibody fucosylation levels, as well as neutrophil E-selectin binding, returned to normal (2 d for neutrophil levels and E-selectin binding and 7 d for normal antibody fucosylation) when the mice no longer received oral 1 (Fig. S9) .
Discussion
The role glycans play in protein function, receptor binding, and cell adhesion has spawned a great deal of research toward the identification of molecules that alter their structures. Aside from the fucose analogues 1 through 4 described here, thiopyranose derivatives (13), fluorinated glucosamines (15), galactoses (7) and sialic acids (11) , azidosugars (1), and glycomimetics (2, 3) have all been used to block the incorporation of natural sugars into glycans or to substitute in their places. These derivatives provide insights into glycoprotein biology and the molecular details of ligand interactions, which can help define new pathways for drug development.
A recent report demonstrating the importance of fucose in cell binding was obtained with compound 2, which was taken up within HL-60 promyelocytic leukemia cells and converted to the GDP derivative 3, resulting in altered glycan structures with diminished E-selectin binding (11) . Our results confirm and augment these in vitro findings, in that we show that 2 and 5 and their deacetylated counterparts 1 and 4 not only inhibit cell membrane fucosylation, but also can be used to form fucose-deficient mAbs with enhanced effector function activities. This is accomplished through inhibition of GMD and Fut8, both of which are involved in mAb fucosylation. In CHO cells, the likely mechanism by which fucosylation is inhibited is through depletion of GDP-fucose, the donor substrate for all Futs. However, inhibition of Fut8 may also be important because 3 and 6 are likely transported into the Golgi apparatus, as suggested by the low but measurable levels of incorporation of each fucose analogue into mAb glycans.
Compound 1 incorporation into mAbs (0.2%) was much lower than that of 4 (3%), a benefit that the 2-fluorofucose analogues have for in vitro generation of mAbs lacking core fucosylation. That 4 is incorporated into mAb glycans at all is consistent with previous reports showing the peracetylated form of this molecule was incorporated into cell surface glycoproteins at low levels (10, 12) . The inhibitors reported here lead to almost complete inhibition of mAb fucosylation, without impairing cell growth or diminishing the amount of mAb generated. Our approach of inhibiting mAb fucosylation in vitro with small molecules that are readily available in kilogram levels complements existing technologies that use engineered cell lines that lack the required enzymes for fucose incorporation. A distinction is that the biochemical inhibitors described here can be used in production cell lines already in place for the generation of fucosylated mAb of interest.
The finding that 1 was orally bioavailable, with no apparent toxicity in mice that received high doses over the course of 3 wk, prompted us to explore its effects on cells and proteins in vivo. As was found in cell culture, the in vivo effects appear to be pluripotent, suggesting that fucosylation was generally inhibited during oral administration. At the protein level, the circulating antibodies in immunocompetent mice were minimally fucosylated. At the cellular level, neutrophil sLeX expression was inhibited, and adhesion to selectins was considerably diminished. Both activities were reversed when drug treatment was discontinued. The lack of overt toxicity after 3 wk of treatment would suggest minimal impact on organ function. A more thorough evaluation of the toxicology and tissue distribution of 1 will be undertaken as we move closer to the clinic. Such studies will include brain tissues, where it is known that intracranial tumors take up radiolabeled fucose to a much greater extent than normal brain tissue (48) .
There are many potential in vivo applications for this technology. The direct antitumor activities of cellular fucosylation inhibitors such as 1 present the possibility of a new approach that merits further pursuit for cancer therapy. Another application uses inhibitors of fucosylation as a means to augment the activities of cancer vaccines through the generation of endogenously produced antitumor antibodies that are fucose-deficient and have enhanced ADCC activities. Clinical precedence for this concept has been demonstrated in patients with lymphoma treated with an idiotype vaccine, in which longer progression-free survival was associated with expression of the high-affinity FcγRIIIA genotype (49) . This genotype is also associated with higher response rates to the anti-CD20 lymphoma antibody rituximab, even in a background of potentially competing antibodies that can also bind to the highaffinity FcγRIIIA receptor (50) . Besides the cancer indications described here, it is possible to envision the use of this fucoseinhibition technology in other diseases such as HIV, in which antibodies lacking fucose are known to be much more active than their fucosylated counterparts (51) . Finally, the demonstration that in vivo administration of fucosylation inhibitors leads to reversible neutrophilia suggests applications in acute inflammatory disease settings. We are currently engaged in further studies to explore this promising therapeutic modality.
Materials and Methods
mAb Production and Fucosylation Analysis. mAbs were expressed and purified from CHO-DG44 cells as described previously (52) with fucose analogues in the culture medium during production. Purified mAbs were reduced (10 mM DTT, 37°C, 15 min) and analyzed by LC-MS via PLRP-S chromatography and electrospray ionization quadrupole TOF MS. Heavy-chain data were deconvoluted by using the MaxEnt1 function in MassLynx 4.0. Peak heights of the G0 and G0F peaks were used for calculation of the percent fucosylated mAb.
Determination of Fucose Analogue Incorporation. The method used to measure fucosylation of antibodies is similar to that in a previously described report (53) . The mAb was reduced (45°C, 30 min, 4.5 M Gn-HCl, 5 mM DTT). Cysteines were alkylated with 11 mM iodoacetamide in the dark at room temperature (1 h) followed by DTT (11 mM, 1 h). Purification was by dialysis against 20 mM NH 4 HCO 3 , pH 7.8, overnight, followed by digestion with trypsin (1:50 wt/wt, 37°C, 8 h) and analysis by LC-MS using a C18 reversed-phase column and electrospray ionization quadrupole TOF MS. Relative abundances of the 3+ and 2+ charge states of the G0, G0F, and G04 were used to determine the percent nonfucosylated and incorporated analogue for the 5-generated mAb. For the 2-generated mAb, the native G0F and G01 have overlapping isotopic distributions. The relative contribution of each species to the isotopic distribution was solved based on the elemental composition of both species. ADCC Assays. ADCC activity was measured using a standard 51 Cr release assay described previously (31) except that enrichment of FcγRIIIA + cells was accomplished by using a human natural killer cell enrichment kit (StemcellTechnologies).
Inhibition of GMD. Radiolabeled GDP-mannose ([mannose 2-3 H], 20 μCi/μmol) was diluted with unlabeled GDP-mannose to 4 μM (0.05 μCi/μL). Reaction buffer (5×, 250 mM Tris, pH 8.0, 25 mM MgCl 2 , 1 mM NADPH, 1 mM NADP+, 25 mM ATP, 50 mM nicotinamide) was mixed with labeled GDP-mannose (1 μM final), varying concentrations of inhibitor (0-100 μM), and recombinant human GMD (50 μg/mL final) in a total volume of 3 μL and incubated at 37°C. After 90°C inactivation (5 min) and dilution 1:10 in water, samples were analyzed by HPLC (C18-reversed phase, Beta-RAM β-detection).
Inhibition of Fut8. Radiolabeled GDP-fucose ([fucose-2-3 H(N)], 58.1 μCi/mmol) was diluted with unlabeled GDP-fucose to 15 μM (0.05 μCi/μL). Reaction buffer (10× 630 mM sodium cacodylate, pH 7, 0.63% Triton X-100, 125 mM MnCl 2 , 30 mM ATP), N-glycan tetrapeptide acceptor (GnGn-Db, 10 μM final, EMD Millipore), labeled GDP-fucose (3 μM final), inhibitor (0-4,000 μM), and recombinant hamster Fut8 (5 μg/mL final, custom from GenScript) were added in a total volume of 5 μL. Incubations at room temperature were stopped by the addition of 200-proof EtOH (6 μL) and water (40 μL), centrifugation, and analysis by HPLC by using a C18 reversed-phase column and Beta-RAM β-detection.
Pharmacodynamic Effects of Oral Treatment with 1. Female BALB/c mice (n = 3 per group) were given oral 1 in their drinking water (1 mM, 10 mM, 100 mM) or left untreated. At day 14, mice were treated with TiterMAX Classic adjuvant and continued to receive the 1-containing water through day 21, when blood was collected. Predose bleeds were collected for baseline comparison. In a second experiment, the animals were given 20 mM 1 in their drinking water (2 wk) and then returned to normal drinking water (1 wk). Terminal bleeds were collected at various time points for analysis.
Total white cells per microliter of blood were determined by hemacytometer using Turk solution [0.01% gentian violet in 3% (vol/vol) acetic acid] to exclude red blood cells. Red blood cells were eliminated by osmotic lysis, and remaining cells were incubated with anti-Gr-1-FITC antibodies and recombinant human E-selectin-Fc fusion. After washing and incubating with PElabeled goat anti-human IgG-Fc, samples were analyzed by flow cytometry. Neutrophil numbers were calculated by using total white cell numbers and the percentage of Gr-1 + cells determined by FACS.
Circulating serum mIgG was isolated by MabSelect Protein A capture. Resin was washed three times with PBS solution, and IgG was eluted with IgG elution buffer (Pierce). Samples (0.5 μg) were dotted onto nitrocellulose membranes. After drying, the membrane was blocked with 5% (wt/vol) BSA/Tris-buffered saline (TBS) solution (1 h), washed with TBS solution containing 0.05% Tween 20 (three times) and incubated with biotinylated AOL (biotinylated by using standard procedures) in 1% BSA/TBS solution (1 h). After three TBS/Tween 20 washes, the membrane was incubated with streptavidin-HRP (30 min), washed, developed by using chemiluminescence reagents, and imaged with a FluorChemQ system. LS174T Xenograft Growth. On day −7, nude female mice (n = 5 per group; Harlan) were provided drinking water containing 50 mM 1. On day 0, naive nude mice (n = 5 per group) and 1-treated mice were injected with 5 × 10 5 LS174T cells per mouse in Matrigel HC 25%.Tumor growth was monitored and measured every 7 d by using calipers. A20 Mouse Lymphoma Study. A20 cells (ATCC) were cultured in RPMI 1640 with 10% FBS, 10 mM Hepes, 1 mM sodium pyruvate, 50 μM 2-mercaptoethanol, and penicillin (100 U/mL)/streptomycin (100 μg/mL). Immunization groups (n = 7 female BALB/c mice; Harlan) were injected s.c. with the KLHFab conjugate (50 μg) with TiterMax adjuvant (1:1 mixture) on day −21 with a boost on day −7. Groups treated with 1 received drinking water containing 20 mM 1 beginning on day −14. One week after the second vaccination (day 0), all mice received 2.5 × 10 6 A20 tumor cells intravenously. Treatment with 1 was continued until day 21, followed by normal drinking water.
